血清寡糖链检测对HBV相关肝细胞癌的诊断价值

张立丽; 金子铮; 刘宁; 赵艳明; 佟瑄; 赵艳; 娄金丽

doi:10.3969/j.issn.1001-5256.2020.04.016

血清寡糖链检测对HBV相关肝细胞癌的诊断价值

DOI: 10.3969/j.issn.1001-5256.2020.04.016

首都医科大学附属北京佑安医院临检中心

详细信息

中图分类号: R512.62;R735.7
计量
- 文章访问数: 1506
- HTML全文浏览量: 28
- PDF下载量: 287
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-18
- 出版日期: 2020-04-20

Clinical value of serum Glycan-Test in the diagnosis of hepatitis B virus-related hepatocellular carcinoma

Clinical Laboratory Center,Beijing YouAn Hospital,Capital Medical University

摘要

摘要: 目的评价寡糖链检测（G-Test）试剂盒（荧光毛细管电泳法）辅助诊断HBV相关肝细胞癌（HCC）的临床价值。方法收集2017年8月-2018年6月就诊于北京佑安医院的患者血清样本310例,其中HBV相关HCC （HCC组） 170例,乙型肝炎肝硬化（肝硬化组） 50例,慢性乙型肝炎（肝炎组） 85例,其他脏器恶性肿瘤（其他恶性肿瘤组） 5例。检测血清寡糖链组分的相对浓度,计算并分析G-Test试剂盒在临床诊断中的灵敏度、特异度、总符合率和阳性预测值、阴性预测值,并与血清AFP进行方法学比较。非正态计量资料多组间比较采用Kruskal-Wallis H检验,进一步两两比较使用Dunn’s多重比较,计数资料两组间比较采用χ2检验。利用受试者工作特征曲线（ROC曲线）对诊断效能进行分析,利用logistic回归建立G-Test与AFP联合诊断模型,受试者工作特征曲线下面积（AUC）的比较采用Z检验。结果 HCC组患者G值[6. 46（5. 73～7. 07）]明显高于肝炎组[3. 38（2. 85～4. 18）]及肝硬化组[3. 99（3. 13～5. 21）]患者（H...
- 寡糖类 /
- 甲胎蛋白类 /
- 癌,肝细胞
Abstract: Objective To investigate the clinical value of the oligosaccharide chain detection kit Glycan-Test( G-Test,fluorescent capillary electrophoresis) in assisting the diagnosis of hepatitis B virus( HBV)-related hepatocellular carcinoma( HCC). Methods A total of310 serum samples were collected from the patients who attended Beijing YouAn Hospital from August 2017 to June 2018,among which there were 170 samples of HBV-related HCC( HCC group),50 samples of hepatitis B cirrhosis( liver cirrhosis group),85 samples of chronic hepatitis B( hepatitis group),and 5 samples of other malignant tumors of visceral organs. The relative concentration of serum oligosaccharide chain was measured,and the sensitivity,specificity,overall coincidence rate,positive predictive value,and negative predictive value of G-Test in clinical diagnosis were calculated and analyzed. A methodological comparison was performed for G-Test and serum alpha-fetoprotein( AFP). The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups,and the Dunn's multiple comparison test was used for further comparison between two groups; the chi-square test was used for comparison of categorical data between two groups. The receiver operating characteristic( ROC) curve was used to evaluate diagnostic efficiency,and the logistic regression model was used to establish a combined diagnostic model of G-Test and AFP. The Z test was used for comparsion of area under ROC curve. Results The HCC group had a significantly higher level of G-Test than the hepatitis group [6. 46( 5. 73-7. 07) vs 3. 38( 2. 85-4. 18),H =107. 9,P <0. 001]and the liver cirrhosis group[6. 46( 5. 73-7. 07) vs 3. 99( 3. 13-5. 21),H = 104. 2,P < 0. 001].The HCC group had a significantly higher AFP level than the hepatitis group [0. 77( 0. 45-1. 77) log10 ng/ml vs 0. 58( 0. 41-0. 89) log10 ng/ml,H = 33. 65,P = 0. 025]. G-Test had a sensitivity of 83. 53%,a specificity of 74. 29%,an overall coincidence rate of 79. 36%,a positive predictive value of 79. 78%,and a negative predictive value of 78. 79%. G-Test alone had a significantly larger AUC than AFP alone( 0. 846 vs 0. 611,Z = 5. 795,P < 0. 001),and G-Test combined with AFP had an AUC of 0. 870,which was significantly larger than that of G-Test alone( Z = 2. 523,P = 0. 012) or AFP alone( Z = 6. 943,P < 0. 001). There were significant differences in the detection rates of G-Test and AFP between the early-stage group and the advanced group( χ2= 26. 441、38. 379,all P < 0. 001). At the negative cut-off values of < 20, < 200,and < 400 ng/ml for AFP,G-Test had a detection rate of 86. 24%,85. 93%,and 85. 31%,respectively,in HCC patients with negative AFP. Conclusion G-Test has good sensitivity and specificity and a certain clinical value in assisting the diagnosis of HCC,and G-Test combined with AFP has better diagnostic efficiency.
- oligosaccharides /
- alpha-fetoproteins /
- carcinoma,hepatocellular

HTML全文

参考文献(17)

[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases Chinese,Medical Association. The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J]. J Clin Hepatol,2015,31(12):1941-1960.(in Chinese)中华医学会肝病学分会，中华医学会感染病学分会．慢性乙型肝炎防治指南(2015年更新版)[J]．临床肝胆病杂志，2015,31(12):1941-1960.

[2] Ministry of Health of the People's Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J]. J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部．原发性肝癌诊疗规范(2011年版)[J]．临床肝胆病杂志，2011,27(11):1141-1159.

[3] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):114-125.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):114-125.

[4] QI J,GAO ZQ,LIU SC,et al. Value of diffusion-weighted magnetic resonance imaging combined with serum tumor markers in diagnosing early primary liver cancer[J]. Chin J Med Offic,2018,46(9):1057-1058.(in Chinese)齐杰，高战强，刘树昌，等．磁共振扩散加权成像联合血清肿瘤标志物对诊断早期原发性肝癌价值分析[J]．临床军医杂志，2018,46(9):1057-1058.

[5] DANIELE B,BENCIVENGA A,MEGN AS,et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma[J]. Gastroenterology,2004,127(5 Suppl 1):s108-s112.

[6] TATEISHI R,SHIINA S,YOSHIDA H,et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers[J]. Hepatology,2006,44(6):1518-1527.

[7] GUPTA S,BENT S,KOHLWES J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis[J]. Ann Intern Med,2003,139(1):46-50.

[8] MARRERO JA,FENG Z,WANG Y,et al. Alpha-fetoprotein,des-gamma carboxyprothrombin,and lectin-bound alphafetoprotein in early hepatocellular carcinoma[J]. Gastroenterology,2009,137(1):110-118.

[9] LIU XE,DESMYTER L,GAO CF,et al. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus[J]. Hepatology,2007,46(5):1426-1435.

[10] FANG M,ZHAO YP,ZHOU FG,et al. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma[J]. Int J Cancer,2010,127(1):148-159.

[11] WANG L,VANHOOREN V,DEWAELE S,et al. Alteration of liver n-glycome in patients with hepatocellular carcinoma[J].Open J Gastroenterol,2012,2(1):1-8.

[12] KOBATA A,AMANO J. Altered glycosylation of proteins produced by malignant cells,and application for the diagnosis and immunotherapy of tumours[J]. Immunol Cell Biol,2005,83(4):429-439.

[13] DENNIS JW,GRANOVSKY M,WARREN CE. Glycoprotein glycosylation and cancer progression[J]. Biochim Biophys Acta,1999,1473(1):21-34.

[14] WARD DG,CHENG Y,N’KONTCHOU G,et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis[J]. Br J Cancer,2006,94(2):287-292.

[15] CAO X,LIU XE,ZHUANG H. Serum N-glycome profiling as markers for diagnosis of liver fibrosis/cirrhosis and hepatocellular carcinoma induced by hepatitis B/C viruses[J]. Chin J Viral Dis,2019,9(3):228-235.(in Chinese)曹曦，刘学恩，庄辉．血清N糖组学标志物诊断乙型和丙型肝炎病毒相关肝纤维化、肝硬化和肝细胞癌[J]．中国病毒病杂志，2019,9(3):228-235.

[16] VANHOOREN V,LIU XE,FRANCESCHI C,et al. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing[J]. Mech Ageing Dev,2009,130(1-2):92-97.

[17] ZHU YP,LU GF,HUANG LN,et al. Value of serum CA125,CA199,CEA,and AFP in differential diagnosis of hepatitis and liver cirrhosis[J]. Shandong Med J,2019,59(1):46-48.(in Chinese)朱壹澎，卢高峰，黄丽娜，等．血清CA125、CA199、CEA、AFP检测在肝炎与肝硬化鉴别诊断中的价值[J]．山东医药，2019,59(1):46-48.

施引文献

资源附件(0)

访问统计